Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00401960
Other study ID # 0507008023
Secondary ID
Status Terminated
Phase Phase 4
First received November 20, 2006
Last updated June 27, 2012
Start date September 2006
Est. completion date October 2008

Study information

Verified date June 2012
Source Weill Medical College of Cornell University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The aim of this study is to determine the safety and efficacy of daptomycin when used as an adjuvant agent to standard care in the treatment of proven native valve Enterococcal endocarditis. Patients with this disease will be offered the option of receiving daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving. The hypothesis of this study is that daptomycin added to standard therapy for Enterococcal endocarditis is safe and efficacious.

Patients who receive daptomycin + standard therapy will be compared to patients who receive standard therapy alone with respect to the following outcomes:

1. Safety.

1. The frequency of any Grade 3 or 4 toxicity (DAIDS scale) will be measured.

2. The frequency of muscle toxicity or renal toxicity, as determined by predefined criteria.

2. Efficacy.

1. Clinical efficacy.

- Time to clearance of bacteremia

- Cure at 6 weeks following completion of antibiotic therapy

- Mortality at 6 weeks following completion of antibiotic therapy

2. Microbiologic efficacy.

- Peak and trough serum bactericidal titers

- The minimum bactericidal concentration of Enterococci to daptomycin

We expect to enroll 40 patients over 2 years.


Recruitment information / eligibility

Status Terminated
Enrollment 6
Est. completion date October 2008
Est. primary completion date October 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age 18 or over

- Definite Enterococcal endocarditis, as defined by modified Duke criteria

- Able to complete follow-up 3 and 6 weeks following completion of intravenous antibiotic therapy

Exclusion Criteria:

- Pregnancy or breast feeding

- Creatine phosphokinase levels over two times the upper limit of normal

- Renal insufficiency or dialysis requirement.

- Presence of chronic indwelling bloodstream catheters or foreign body devices suspected as primary or secondary sites of enterococcal infection unamenable to removal or replacement

- Inability to discontinue or abstain from use of a HMG CoA reductase inhibitor during the study period.

- Hypersensitivity to any of the study medications.

- Any condition that, in the investigator's opinion, may interfere with protocol compliance including, but not limited to, active substance abuse and/or dementia.

- Prosthetic valve endocarditis

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Daptomycin
daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis

Locations

Country Name City State
United States NewYork-Presbyterian Hospital, Weill Cornell Campus New York New York

Sponsors (1)

Lead Sponsor Collaborator
Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary frequency of any Grade 3 or 4 toxicity (DAIDS scale) weekly Yes
Primary frequency of muscle toxicity or renal toxicity, as determined by predefined criteria weekly Yes
See also
  Status Clinical Trial Phase
Terminated NCT00695903 - Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia Phase 2
Recruiting NCT05644990 - T2MR PCR Detection of ESKAPE Pathogens in Patients With Pyogenic Spondylodiscitis and Infective Endocarditis
Recruiting NCT04840225 - Anemia in Patients With Endocarditis
Completed NCT00524212 - How to Improve Diagnosis in Infective Endocarditis N/A
Completed NCT03048643 - Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis N/A
Completed NCT00144885 - IMAGE-Endocarditis: Resonance Magnetic Imaging at the Acute Phase of Endocarditis N/A
Completed NCT03306225 - Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients
Active, not recruiting NCT05522764 - Predictors of Infective Endocarditis Among Patients Managed for Staphylococcus Aureus Bacteremia, Particularly Staphylococcus Aureus Bacteriuria, and Time to Blood Culture Positivity
Terminated NCT04222257 - Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis Phase 4
Not yet recruiting NCT05152225 - Neurological Complication of Infective Endocarditis: A Prospective Multi-site Cohort Study
Not yet recruiting NCT05613933 - Effectiveness of Antibiotic Prophylaxis of Infective Endocarditis for Invasive Dental Procedures in Patients With Prosthetic Heart Valves and/or History of Infective Endocarditis N/A
Recruiting NCT02979951 - Fosfomycin i.v. for Treatment of Severely Infected Patients
Active, not recruiting NCT06434012 - Barts Endocarditis Research Registry
Recruiting NCT06250985 - New Treatment of Cardiac Device Infections; Immediate Reimplantation After Removal of Infected System Phase 3